Aliskiren

證據等級: L5

預測適應症: 7 個

Aliskiren: From Hypertension to Pulmonary Hypertension Owing to Lung Disease and/or Hypoxia

One-Sentence Summary

Aliskiren is the first oral direct renin inhibitor (DRI), originally indicated for the treatment of primary hypertension in adults by blocking the rate-limiting enzyme of the renin-angiotensin-aldosterone system (RAAS). The TxGNN model predicts it may be effective for Pulmonary Hypertension Owing to Lung Disease and/or Hypoxia, with 0 clinical trials and 20 publications retrieved — however, none of the publications directly address aliskiren for this specific indication, placing this prediction at model-only (L5) evidence.

Quick Overview

Item	Content
Original Indication	Hypertension (not registered in Saudi Arabia)
Predicted New Indication	Pulmonary Hypertension Owing to Lung Disease and/or Hypoxia
TxGNN Prediction Score	99.98%
Evidence Level	L5 — Model prediction only, no targeted studies
Saudi Arabia Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available from the regulatory database for this report. Based on established pharmacology, aliskiren is a direct renin inhibitor — it binds to the active site of renin, blocking its cleavage of angiotensinogen to angiotensin I, and thereby reducing the downstream production of angiotensin II and aldosterone. This upstream blockade of the entire RAAS cascade distinguishes it from ACE inhibitors and ARBs, which act at later steps in the same pathway. Its approved use in hypertension reflects this mechanism.

The theoretical connection between aliskiren and pulmonary hypertension owing to lung disease and/or hypoxia (WHO Group 3 PH) is, however, weak. The dominant pathophysiological drivers in Group 3 PH are hypoxic pulmonary vasoconstriction (HPV), HIF-1α pathway activation, endothelin-1/nitric oxide imbalance, and progressive pulmonary vascular remodeling — pathways in which RAAS plays a peripheral rather than central role. While angiotensin II does exert some vasoconstrictive effect in the pulmonary vasculature, it is not the rate-limiting driver of hypoxia-induced right-sided pressure elevation. RAAS blockade alone is unlikely to meaningfully reverse HIF-1α–driven remodeling.

The 20 publications retrieved from PubMed were identified via broad keyword association with "hypoxia" and represent general background literature on hypoxia biology in neurological, oncological, and physiological contexts. None specifically investigates aliskiren in pulmonary hypertension. The high TxGNN score therefore reflects graph-network inference from disease-drug structural similarity rather than direct experimental evidence, and should be interpreted as a hypothesis-generating signal only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

⚠️ The publications below were retrieved by hypoxia-related keyword matching. None directly investigates aliskiren for pulmonary hypertension owing to lung disease and/or hypoxia — they provide general mechanistic background on hypoxia pathophysiology only.

PMID	Year	Type	Journal	Key Findings
11172576	2000	Review	Respiratory Care Clinics of North America	Describes the four core mechanisms of hypoxemia (V/Q mismatch, shunt, hypoventilation, low FiO₂); foundational reference for understanding Group 3 PH pathophysiology
21328446	2011	Review	Journal of Cellular Biochemistry	Summarizes how hypoxia drives angiogenesis, metabolic reprogramming, pH homeostasis, and vascular disease; contextualizes HPV and downstream remodeling
34535359	2021	Review	Clinical Oncology	Reviews therapeutic strategies modifying tumor hypoxia; discusses why HIF-1α activation confers resistance — applicable reasoning for Group 3 PH mechanisms
31961750	2020	Review	Annual Review of Immunology	Explores the HIF axis in innate immunity and inflammatory hypoxia; relevant to pulmonary vascular inflammatory remodeling in chronic lung disease
33862277	2021	Review	Ageing Research Reviews	Reviews dual protective/injurious role of hypoxia across organ systems; discusses systemic consequences of pulmonary hypoxemia
34618295	2022	Review	Metabolic Brain Disease	Molecular mechanisms of acute and chronic hypoxia-induced dysfunction; provides biochemical context for chronic hypoxia sequelae
31706510	2019	Review	Trends in Cancer	Deubiquitinases regulate HIF-1α stability; discusses ubiquitin-proteasome control of hypoxia signaling — background for HIF-driven pulmonary remodeling
40347693	2025	Review	Redox Biology	Hypoxia-vascular dysfunction interplay in multiple sclerosis; highlights how inflammatory hypoxia differs from ischemic hypoxia — relevant distinction for PH subtypes
40815459	2025	Commentary	Revista Médica del IMSS	Physiological acclimatization to hypobaric hypoxia at altitude; discusses morphological and genetic adaptations relevant to chronic hypoxemia models
37328448	2023	Basic Science	Advanced Science	NAT10/HIF-1α positive feedback drives glycolysis in hypoxic cancer cells; illustrates how HIF-1α creates self-sustaining hypoxia tolerance — applicable to vascular cell biology

Safety Considerations

Please refer to the package insert for safety information.

Critical safety signal from published evidence: The ALTITUDE trial (aliskiren in type 2 diabetes with cardiovascular or renal disease) was terminated early due to excess non-fatal strokes, hypotension, hyperkalemia, and acute kidney injury in patients receiving aliskiren combined with an ACE inhibitor or ARB. This combination is now contraindicated. Any repurposing study in patients with pulmonary disease and likely comorbid cardiovascular or renal conditions must explicitly evaluate dual RAAS blockade risk and screen for bilateral renal artery stenosis.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a near-maximum TxGNN score (99.98%), the mechanistic connection between RAAS inhibition and Group 3 pulmonary hypertension is weak — the dominant pathology (HPV, HIF-1α, endothelin/NO imbalance) is not RAAS-driven — and no clinical trials or targeted literature support this specific indication, confirming L5 evidence status.

To proceed, the following is needed:

Preclinical proof-of-concept in established Group 3 PH animal models (e.g., SU5416/hypoxia rat model or MCT model) to test whether renin inhibition modulates pulmonary vascular pressure
Mechanistic studies clarifying whether RAAS contributes to HIF-1α activation or endothelin upregulation in chronic hypoxic lung disease
Full MOA documentation from DrugBank to complete mechanistic gap analysis (DG002)
SFDA/package insert safety data retrieval to complete S1 safety screening (DG001)
Formal safety screening against renal function and cardiovascular comorbidity profile typical of Group 3 PH patients, given ALTITUDE trial risks

Higher-priority indications from this Evidence Pack: Malignant Renovascular Hypertension (rank 4, L4 — strong RAAS mechanistic alignment) and Cerebrovascular Disorder (rank 7, L3 — 2 clinical trials including a Phase 2/3 MRI study, 13 publications, and direct animal neuroprotection data) demonstrate substantially better evidence and mechanistic fit. These indications are recommended for prioritization over the top-ranked TxGNN prediction.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.